Stockscreener 앱 받기
3.46
3.89%
-0.14
전일 마감가:
$3.60
열려 있는:
$3.5
하루 거래량:
3,559
Relative Volume:
0.23
시가총액:
$3.62M
수익:
-
순이익/손실:
$-7.29M
주가수익비율:
-0.142
EPS:
-24.3686
순현금흐름:
$-6.81M
1주 성능:
+3.28%
1개월 성능:
+27.75%
6개월 성능:
+21.83%
1년 성능:
-61.04%
1일 변동 폭
$3.4511
$3.50
1주일 범위
$3.37
$3.655
52주 변동 폭
$2.36
$13.50
Heartsciences Inc Stock (HSCS) Company Profile
명칭
Heartsciences Inc
전화
682-237-7781
주소
550 RESERVE ST, SUITE 360, SOUTHLAKE
HSCS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HSCS
Heartsciences Inc
|
3.4519 | 3.62M | 0 | -7.29M | -6.81M | -24.37 |
|
ABT
Abbott Laboratories
|
132.43 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.38 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.62 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.62 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.42 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Heartsciences Inc 주식(HSCS)의 최신 뉴스
HeartSciences (HSCS) Unveils MyoVista Insights Platform | HSCS S - GuruFocus
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program - The Manila Times
HeartSciences launches MyoVista Insights platform - TipRanks
Lifestyle Icon Martha Stewart Confirmed As Vivid Sydney 2025's Global Storyteller - Barchart.com
This AI Company Is Solving A 100+ Year-Old Health Problem - Barchart.com
Northstar Secures 15-Year Lease Extension For Delta, BC Facility - Barchart.com
/R E P E A T -- LASSONDE INDUSTRIES INC. WILL HOLD A CONFERENCE CALL TO DISCUSS ITS Q4 AND FISCAL 2024 RESULTS/ - Barchart.com
HeartSciences faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
HeartSciences faces Nasdaq delisting over equity shortfall - Investing.com
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results - The Manila Times
HeartSciences Reports Third Quarter Fiscal 2025 Financial Results and Business Update on AI-Powered ECG Innovations - Nasdaq
HeartSciences Q3: AI-ECG Breakthrough Nears FDA Milestone as CMS Backs Reimbursement - StockTitan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications - The Manila Times
AI Medical Tech Firm HeartSciences Strengthens Investor Communications Strategy - StockTitan
HeartSciences grants stock options to executives and directors - MSN
HeartSciences grants stock options to executives and directors By Investing.com - Investing.com South Africa
Becton, Dickinson And Company's Q1 2025 Earnings: What To Expect - Barchart.com
Scientists Discover Heart-Saving Powers in Olive, Grape, Garlic, Rosemary, and Saffron - SciTechDaily
HeartSciences Inc. withdraws IPO registration - Investing.com
HeartSciences Inc. withdraws IPO registration By Investing.com - Investing.com UK
Biogen Stock: Is BIIB Underperforming The Healthcare Sector? - Barchart.com
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results - The Manila Times
HeartSciences Advances AI-Powered ECG Platform, FDA Submission Set for Q1 2025 - StockTitan
Anteris Technologies Prices $88.8M Nasdaq IPO for Revolutionary Heart Valve Development - StockTitan
Bill Otten Joins Hello Heart as Commercial President - Medical Product Outsourcing
David Chung Lands Top Job at Heart Repair Technologies - Medical Product Outsourcing
HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement - The Manila Times
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement - GlobeNewswire
HeartSciences Secures $125 Medicare Reimbursement for AI-ECG Tech, Awaits FDA Nod | HSCSW Stock News - StockTitan
HeartSciences shareholders approve auditor and meeting adjournment - Investing.com India
HeartSciences shareholders approve auditor and meeting adjournment By Investing.com - Investing.com UK
Clear Secure: Q3 Earnings Snapshot - Barchart.com
Investor Alert: Halo Collective, Inc. And Its Missing Continuous Disclosure Documents - Barchart.com
Heart Test Laboratories announces corporate name change to HeartSciences - Investing.com India
What To Expect From Pfizer's Q3 2024 Earnings Report - Barchart.com
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Earnings Preview: What To Expect From Intuitive Surgical's Report - Barchart.com
Why Maison Solutions Shares Are Trading Higher By Around 91%; Here Are 20 Stocks Moving Premarket - Benzinga
Shares of HeartSciences get a bump from announcement of non-dilutive financing - Kursiv Media
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results - GlobeNewswire
HeartSciences reports fiscal 2024 financial results - Medical Buyer
HSCSHeartSciences Inc Latest Stock News & Market Updates - Stock Titan
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare - GlobeNewswire
HeartSciences Adds Another International Patent to its IP Portfolio - MPO-mag
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction - Diagnostic and Interventional Cardiology
Alexandria Real Estate Equities, Inc. Releases 2023 Corporate Responsibility Report Highlighting Its Longstanding Leadership at the Vanguard and Heart of the Life Science Industry - PR Newswire
Cardiomatics Cooperates with the Biotronik Sales Organization in Germany to Accelerate the Growth of its Leading AI-powered ECG Analysis Solution in the German Market - Diagnostic and Interventional Cardiology
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio - GlobeNewswire
HeartSciences’ MyoVista Wavelet Technology Now Protected in Canada - MPO-mag
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG - Diagnostic and Interventional Cardiology
Heartsciences Inc (HSCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
9.59%
0.04%
자본화:
|
볼륨(24시간):